Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities

Monica Margoni, Francesca Rinaldi, Paola Perini, and Paolo Gallo

Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.

Keywords: pediatric onset multiple sclerosis, first-line therapies, second-line therapies, efficacy, safety

INTRODUCTION

High relapse rate, rapid accumulation of white (WM) and gray matter (GM) damage, and worse long-term physical and cognitive disability are typical features of pediatric-onset multiple sclerosis (POMS) (1–6). Despite neuroplasticity, POMS patients reach similar levels of disability at a younger age than adult-onset MS (AOMS), and their quality of life (QoL) is frequently significantly compromised, with negative impacts on school, social, and physical activities (5, 7). Accordingly, POMS has to be considered a severe, highly disabling disease, with extremely high social costs. Approximately, POMS accounts for 2–10% of all MS cases (5), but incidence of MS in children and adolescents is increasing, and it has become relatively frequent to face the diagnosis and the treatment of this peculiar population.

Since no definite guideline exists on the management of POMS, treatment strategies often reflect the center-specific experience as well as the neurologist’s therapeutic attitude and knowledge that derive from the application of adult-tailored MS therapeutic protocols. Despite heterogeneity, data on efficacy and safety of disease-modifying drugs (DMDs) [e.g., interferon beta (IFN β), glatiramer acetate (GA), natalizumab (NTZ), and rituximab] in POMS collected from single- or multi-center open-label observational studies indicate a marked effect on clinical and magnetic resonance imaging (MRI) parameters of inflammation (8–11), especially when therapy is initiated very early (12), as also pointed out by the 2012 International Pediatric MS Study Group (IPMSSG) consensus (13).

Recently, the US Network of Pediatric MS Centers reported data on 741 POMS patients, 197 treated with newer therapies [fingolimod, dimethyl fumarate (DMF), teriflunomide, NTZ, rituximab, and ocrelizumab] and 544 treated with IFN β or GA. As expected, those on newer DMDs had significant lower annualized relapse rate (ARR) than those with IFN β or GA (p < 0.001) (14). Moreover, a high rate of IFN β and GA treatment failure has been reported in POMS, ranging from 25 to 64% across studies (15). It is noteworthy that many of these drugs are still used off-label;
thus, the recent approval of fingolimod for POMS by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) constitutes a significant step forward in treating these patients (16).

Finally, the QoL must be strongly taken into consideration when treating POMS with DMDs. Therapies that induce symptoms (fever, headache, myalgias, etc.) that negatively and persistently impact school and sport performances, and therefore substantially modify the QoL, must be avoided or interrupted early.

Here, we review the state of the art of POMS therapy and focus on the newer therapies (oral and infusion DMDs) and on those currently under trial.

**FIRST-LINE THERAPIES**

**Injectables**

IFN \(\beta\) and GA (hereafter called injectables) are the most widely used DMDs in POMS (17–19). Both drugs showed a high-efficacy profile in the short term (see Table 1 for a comprehensive overview) (18, 20–23, 28, 29) but also a consistent rate of treatment failure in the medium/long term. The US and Italian Network of the MS Centers collected longitudinal data on injectable-treated POMS, summarized in two reports: (1) after a mean follow-up of 3.9 years, 114 (44.2%) of 258 patients had their therapy changed to a second DMDs owing to refractory disease (27.9%) or poor tolerability of a first-line DMDs (16.3%) (30); (2) after a follow-up of 12.5 years, 82/97 (84.5%) patients needed a therapy switch, that in up to 58% of cases, was an immunosuppressive/second-line drug (9).

The US Network of Pediatric MS Centers analyzed 618 DMD-treated patients and reported that 147/483 (30.4%) of those treated with injectables switched to other therapies in a mean follow-up of 3.5 years (17). More recently, in a cohort of 741 patients, the 197 who were commenced on newer therapies (DMF, fingolimod, teriflunomide, NTZ, rituximab, and ocrelizumab) had significantly lower ARR than the 544 on injectable, confirming the higher efficacy of the newer therapies (14).

Although injectables are not associated with increased risk of infections or malignancies and the most reported side effects are injection site reactions for GA and flu-like symptoms for IFN \(\beta\) (25–35%) (19, 31), the loss of adherence (i.e., missing > 20% of doses) is high and is more frequently reported by patients (up to 41%) than by parents (14%) or pharmacist (7%) (15). Expert opinion suggests that IFN \(\beta\) is better tolerated if initiated at 25–50% of the standard dose followed by a gradual escalation to full dose over 1 to 3 months (32).

**Orals**

**Dimethyl Fumarate**

A phase II multicenter study (FOCUS) (25) with DMF (120 mg twice daily on days 1–7, 240 mg twice a day thereafter) on 22 POMS (20 of which completed the study) showed a median change in number of new/enlarged T2 hyperintense lesions of −2.0 at week 24 compared with baseline (−1.5 vs. −8.0, \(p = 0.009\)). The unadjusted ARR was 1.5 in the year prior to study and 0.8 at week 24. Adverse events (AEs) (most commonly gastrointestinal disorders and flushing) and pharmacokinetic (PK) were consistent with those observed in adults (25). The good safety and tolerability profiles of DMF were confirmed, in agreement with a previous small retrospective study on nine patients (24).

In the CONNECTED study (26), extension of FOCUS, a long-lasting benefit of therapy, was observed: 12/17 participants (71%) had no new/enlarged T2 hyperintense lesions from weeks 16 to 24. Over a mean treatment period of 120 weeks, a significant reduction of ARR compared with the year before DMF initiation was observed (from 1.5 to 0.2, \(p < 0.0001\)). AEs were reported in 18 patients (90%) during the 24-week follow-up (the most frequent being flushing, observed in 25% of the patients). However, no patient experienced severe AEs (SAEs) leading to DMF discontinuation.

A phase III, double-blind, placebo-controlled, three-arm randomized controlled trial (RCT) aiming on evaluating safety and efficacy of DMF compared with placebo and pegylated IFN \(\beta\)-1a is currently recruiting patients (ClinicalTrials.gov Identifier: NCT03870763).

**Teriflunomide**

The results of a 96-week, double-blind, placebo-controlled, phase III RCT evaluating efficacy, safety, and PK of teriflunomide in 109 POMS aged 10–17 years (TERIKIDS) have been presented at ECTRIMS 2020 (27).

Teriflunomide numerically reduced the risk of clinical relapse by 34% relative to placebo, but this did not reach statistical significance (\(p = 0.29\)). Conversely, teriflunomide reduced the risk of the time of clinical relapse or switch due to high MRI activity by 43% (\(p = 0.041\)) and the appearance of Gd-enhancing and new/enlarged T2 hyperintense lesions compared with placebo (1.9 vs. 7.5, \(p < 0.0001\) and 4.7 vs. 10.5, \(p = 0.0006\), respectively). Three SAEs were observed [pulmonary tuberculosis, acute pancreatitis, and alanine aminotransferase (ALT) increase].

The open-label extension of this RCT is currently in progress. An interim analysis on 100 patients demonstrated that the time to first confirmed relapse and the 24-week sustained disability progression were numerically lower for the teriflunomide/teriflunomide (T/T) arm compared with the placebo/teriflunomide (P/T) arm but did not reach the significance (46.0 vs. 64.0%, \(p = 0.098\) and 17.4 vs. 29.3%, respectively).

Furthermore, new/enlarged T2 hyperintense and Gd-enhancing lesions were significantly reduced in the T/T arm (6.3 vs. 13.0, \(p = 0.0006\), and 1.9 vs. 4.2, \(p = 0.0106\), respectively). The incidence of AEs was higher in the P/T arm compared with the T/T arm during the open-label period (82.7 vs. 68.0%, respectively). Two SAEs were recorded (acute pancreatitis; increased amylase and lipase). Although teriflunomide proved to be well-tolerated and disclosed a manageable safety profile, the SAEs mentioned above suggest that if this medication is ultimately approved, an adequate surveillance of biological
### TABLE 1 | Observational and clinical studies on first-line immunomodulatory therapies in pediatric multiple sclerosis.

| Treatment       | First author            | Year  | Trial design                        | Number of patients | Clinical findings | MRI findings | Adverse effects |
|-----------------|-------------------------|-------|------------------------------------|--------------------|-------------------|--------------|-----------------|
| IFN β           | Mikaeloff et al. (20)   | 2001  | Prospective study (median FU 1 year)| 16 RRMS            | Stable EDSS       | Stable T2 lesions in 3 patients | Fever: 50% Headache: 28% Myalgia: 17% Fatigue: 5% <10% of patients |
|                 |                         |       |                                    |                    | ↓ APR (3.29 ± 2.3 at b vs. 0.88 ± 0.8 at FU in Rebi-fBetaferon) | T2 lesions in 6 patients |                  |
|                 |                         |       |                                    |                    | ↓ APR (2.49 ± 1.4 at b vs. 0.49 ± 0.5 at FU in Avonex) | –               |                  |
|                 | Ghezzi et al. (21)      | 2005  | Prospective study (mean FU 34.4 ± 25.0 months in Rebi-fBetaferon, 23.3 ± 13.4 months in Avonex) | 18 RRMS            | –                 | –             | Flu-like syndrome (35%), abnormal liver function test (26%), and injection site reaction (21%) No SAE |
|                 |                         |       |                                    |                    | ↑ ARR (1.7 at b vs. 0.04 at y5) | –               | 96% of patients (58% flu-like syndrome, 17% myalgia/arthaigia) |
|                 | Banwell et al. (19)     | 2006  | Retrospective study (mean FU 29.2 months) | 43 RRMS            | –                 | –             |                  |
|                 | Tenambbaum et al. (18)  | 2006  | Open-label, prospective, single-center study (6 years) | 24 RRMS            | ↓ ARR (2.89 ± 1.3 at b vs. 0.28 ± 0.36 at FU) | T2 lesions in 2/7 T2 lesions in 3/7 | –               |
|                 |                         |       |                                    |                    | –                 | –             |                  |
|                 | Mikaeloff et al. (22)   | 2008  | Prospective study (mean FU 5.5 years) | 197 RRMS           | ↓ Rate of the first attack during the first year of treatment (hazard ratio: 0.31, 95% confidence interval: 0.13–0.72) and 2 years (0.40, 0.20–0.63) | –               | –               |
|                 |                         |       |                                    |                    | T2 lesions in 2/7 | T2 lesions in 3/7 |                  |
|                 | Ghezzi et al. (21)      | 2005  | Prospective study (mean FU 33.3 ± 27.6 months) | 9 RRMS             | ↓ ARR (2.89 ± 1.3 at b vs. 0.28 ± 0.36 at FU) | –               | –               |
|                 |                         |       |                                    |                    | –                 | –             |                  |
| Dimethyl fumarate | Makhani et al. (24)     | 2016  | Retrospective study (median FU 15 months) | 13 RRMS            | ↓ ARR in 8/13 children | New T2 lesions in 33%, one of whom had been non-adherent to treatment | 8/13 (62%) flushing 7/13 (54%) GI discomfort, 3/13 rash (23%), 2/13 malaise (15%) 73% of patients (abdominal pain, nausea, vomiting, flushing) No SAE 90% AEs (flushing in 25%) No SAE |
|                 |                         |       |                                    |                    | –                 | –             |                  |
|                 | Alroughani et al. (25)  | 2018  | Phase II, single arm, multicenter, open label (FOCUS) (24 weeks) | 22 RRMS            | ↓ ARR (1.5 at b vs. 0.8 at 24 weeks) | ↓ New/enlarged T2 hyperintense lesions (−1.5 at b vs. −8.0 at 24 weeks, p = 0.009) | 88.1% AEs 3 SAEs (pulmonary tuberculosis, acute pancreatitis, ALT increase) |
|                 |                         |       |                                    |                    | ↓ New/enlarged T2 hyperintense lesions (−1.5 at b vs. −8.0 at 24 weeks, p = 0.009) | –               | –               |
|                 | Alroughani et al. (26)  | 2020  | Extension study of FOCUS (CONNECTED) (96 weeks) | 20 RRMS            | ↓ ARR (1.5 at b vs. 0.2 at 120 weeks, p < 0.0001) | 12/17 (71%) no new/enlarged T2 hyperintense lesions from w16 to w24 | –               |
|                 | Teriflunomide           |       |                                    | 109 RRMS           | ↓ Clinical relapse by 34% (p = 0.29) Time of relapse or switch due to high MRI activity by 43% (p = 0.041) | ↓ Gd+ and new/enlarged T2 hyperintense lesions (1.9 vs. 7.5, p < 0.0001 and 4.7 vs. 10.5, p = 0.0006, respectively) compared with Pbo | 88.1% AEs 3 SAEs (pulmonary tuberculosis, acute pancreatitis, ALT increase) |
|                 | Chitnis et al. (27)     | 2020  | Double-blind, randomized, placebo-controlled Phase III (TERIKIDS) (96 weeks) | 109 RRMS           | ↓ First confirmed relapse and 24-week sustained disability progression compared with Pbo/Ter (46.0 vs. 64.0% and 17.4 vs. 29.3%) | ↓ Gd+ and new/enlarged T2 hyperintense lesions in the Ter-treated group (1.9 vs. 4.2, p = 0.0106, 6.3 vs. 13.0, p = 0.0006) | ↑AEs in the Pbo/Ter compared with the Ter/Ter (82.7% vs. 68.0%) 2 SAEs (acute pancreatitis, amylose and lipase increased) |
|                 |                         |       |                                    |                    | ↓ Time of relapse or switch due to high MRI activity by 43% (p = 0.041) | ↓ Gd+ and new/enlarged T2 hyperintense lesions in the Ter-treated group (1.9 vs. 4.2, p = 0.0106, 6.3 vs. 13.0, p = 0.0006) | ↑AEs in the Pbo/Ter compared with the Ter/Ter (82.7% vs. 68.0%) 2 SAEs (acute pancreatitis, amylose and lipase increased) |

B, baseline; EDSS, Expanded Disability Status Scale; FU, follow-up; GA, glatiramer acetate; IFN β, interferon β; Pbo, placebo; RR, relapse rate; RRMS, relapsing-remitting multiple sclerosis; Ter, teriflunomide.
parameters in treated patients is necessary. Finally, the placebo-controlled design for TERIKIDS raised some concerns on its inherent limiting ability to compare clinical trials with one another (33). Further studies with an active comparator and other MRI endpoints (e.g., annualized rate of brain atrophy) are warranted to further define the efficacy and safety profile of teriflunomide.

SECOND-LINE THERAPIES

Orals
Fingolimod
The randomized, double-blind, phase III RCT PARADIGMS (34) compared fingolimod with intramuscular (i.m.) IFN β-1a in a cohort of 215 patients (34). This study demonstrated a significant reduction of the adjusted ARR in the 107 patients treated with fingolimod compared with those treated with IFN β-1a (0.12 vs. 0.67, p < 0.001). Furthermore, new/enlarged T2 hyperintense lesions were reduced in fingolimod patients compared with IFN β-1a (4.39 vs. 9.27, p < 0.001). AEs occurred in 88.8% of patients who received fingolimod and in 95.3% of those who received IFN β-1a. SAEs occurred in 18 patients (16.8%) in the fingolimod group and included four cases of infections (appendicitis, cellulitis, gastrointestinal infection, oral abscess, viral infection, and viral pharyngitis) and six (5.6%) cases of convulsions [vs. 1 (0.9%) in the IFN β-1a arm]. Other SAEs in the fingolimod group included single cases (0.9%) of agranulocytosis, arthralgia, autoimmune uveitis, bladder spasm, dyspepsia, dysuria, elevated alanine aminotransferase level, elevated γ-glutamyl transferase level, gastrointestinal necrosis (intussusception or necrotic bowel), head injury, humerus fracture, hypersensitivity vasculitis, migraine, migraine without aura, muscular weakness, rectal tenesmus, second-degree ativoventricular block, and small-intestinal obstruction and two cases of leukopenia (1.9%).

In a secondary analysis on MRI parameters (16), fingolimod demonstrated a reduction in the annualized rate of formation of new/enlarged T2 hyperintense lesions (52.6%, p < 0.001), number and annualized rate of T1 hypointense lesions (66% and p < 0.001; 62.8% and p < 0.001, respectively), and combined unique active lesions (60.7%, p < 0.001) vs. IFN β-1a. Furthermore, the percent increase in T2 (18.4 vs. 32.4%, p < 0.001) and Gd-enhancing T1 lesion (−72.3 vs. 4.9%, p < 0.001) volumes and the annualized rate of brain atrophy (−0.48 vs. −0.80%, p = 0.014) were lower with fingolimod vs. IFN β-1a.

Prior to PARADIGMS, data from two small observational studies were available. In a study on 23 highly active POMS patients treated with fingolimod (35), a significant decrease in ARR (75%), new T2 hyperintense (81%), and Gd-enhancing (93%) lesions compared with pretreatment was reported. Noteworthy, seven patients with very high disease activity at clinical presentation experienced disease re-activation when switching from NTZ to fingolimod after a 2-month washout period. Six of them were further switched to alemtuzumab during the follow-up. These data suggested that very active POMS does not probably respond to fingolimod and needs to be treated with more potent immunosuppressive drugs. No SAE was reported in this study. In a second study conducted on 17 POMS treated with fingolimod for an average of 8.6 months, the majority of the patients remained free of clinical or radiological activity. An improvement in Expanded Disability Status Scale (EDSS) score compared with pretreatment was also observed (range of change −3 to −0.5) (36).

All together, these observations suggest fingolimod to be effective and well-tolerated in most POMS.

Cladribine
No data are currently available on cladribine-treated POMS.

Infusion Therapies
Natalizumab
Following the approval of fingolimod, in Italy, NTZ has been approved for POMS aged 12–17, having active and rapidly evolving MS not responsive to fingolimod, or in the presence of contraindications or persistent side effects due to fingolimod. No RCT has been conducted on POMS to date, but several observational studies have focused on NTZ efficacy and safety in these patients (see Table 2 for a comprehensive overview).

The largest cohort of NTZ-treated POMS included 101 patients, having a mean age at onset of 12.9 ± 2.7 years and a mean EDSS of 2.6. Sixty-six percent had been previously treated with first-line DMDs. Patients were treated with NTZ for a mean period of 34.2 ± 18.3 months (40). Compared with baseline, a significant reduction in the mean ARR (from 2.3 ± 1.3 to 0.1 ± 0.3, p < 0.001) and new Gd-enhancing lesions (82.8 vs. 10.6%, p < 0.001) were observed at the end of the follow-up (40). Moreover, the no evidence of disease activity (NEDA)-3 status (i.e., no clinical relapses, no increase in disability, and no MRI activity) was achieved in 58% patients. These observations were confirmed in other observational studies (37–39, 41, 47). Recently, we studied the achievement of the NEDA-3 plus status, which includes cognition in the NEDA-3 (the cognitive decline was defined as a decrease of at least four points in the Symbol Digit Modality Test), in 20 naïve POMS treated with NTZ. We observed that 17/20 (85%) and 18/20 (80%) of patients achieved NEDA-3 plus at months 12 and 24, respectively (41).

NTZ was found to be well-tolerated and safe in POMS patients. In some studies, no clinical AE was experienced (39, 47). An open-label, multiple-dose, multicenter prospective study aimed to evaluate the PK/pharmacodynamic (PK/PD) profile, safety, and tolerability of NTZ in POMS, aged 10–18 years, demonstrated similar profiles in adults and pediatric patients in the short term (48). Longer studies, also including a larger number of younger subjects (aged 10–12 years), are required to further inform about long-term PK and PD parameters in POMS. Recently, some concerns about immunosuppression in MS were raised during the coronavirus disease 2019 (COVID-19) pandemic. In our experience, NTZ did not expose POMS to a higher risk of SARS-CoV-2 infection or to a clinically overt/severe disease (49).

At present, no cases of progressive multifocal leukoencephalopathy (PML) have been reported in POMS patients treated with NTZ. The prevalence of JCV
seropositivity in POMS was reported to be higher [ranging from 39 to 51.6% (39, 40, 50)] than in the general healthy pediatric population [21% (51)] but lower than in AOMS patients (52).

While tolerability and safety data are reassuring and clearly indicated that NTZ can be considered the treatment of choice for very active POMS, long-term safety data on larger cohort of patients are needed, especially for evaluating the risk of PML.

### Table 2: Observational and clinical studies on second-line immunomodulatory therapies in pediatric multiple sclerosis.

| Treatment       | First author Year | Trial design | Number of patients | Clinical findings | MRI findings | Adverse effects |
|-----------------|-------------------|--------------|--------------------|-------------------|--------------|----------------|
| Natalizumab     | Kornek et al. (37) 2013 | Retrospective study (mean FU 11 months) | 20 RRMS | ↓ ARR (3.7 at b vs. 0.04, p < 0.001) ↓ EDSS (2 at b vs. 1; p < 0.02) | ↓ T2 lesions (7.8 at b vs. 0.5; p < 0.001) | 50% (headache, asthenia, infections, and hypersensitivity) |
| Arnaal-Garcia et al. (38) 2013 | Retrospective study (mean FU 17 months) | 8 RRMS | ↓ ARR (3 at b vs. 0) ↓ EDSS (3 at b vs. 1) | No Gd+ lesion at FU | 3 AEs |
| Ghezzi et al. (39) 2013 | Retrospective study (mean FU 26 months) | 55 RRMS | 3 relapses ↓ EDSS (2.7 at b vs. 1.9, p < 0.001) | 88% free from radiological disease | Transthy AEs in 22/55 patients (headache, upper respiratory disorders, vertigo) |
| Ghezzi et al. (40) 2015 | Retrospective study (mean FU 26 months) | 101 RRMS | ↓ ARR (2.3 ± 1.0 at b vs. 0.1 ± 0.3, p < 0.001) ↓ EDSS (2.6 ± 1.3 at b vs. 1.8 ± 1.2, p < 0.001) | T2/Gd+ lesions were observed in 10/91 (10.9%) patients at 6 months, 6/67 (9.0%) at 12 months, 2/61 (3.3%) at 18 months, 2/68 (2.9%) at 24 months, 3/62 (4.8%) after 30 months | AEs in 36/101 patients (headache, upper respiratory disorders, vertigo) |
| Margoni et al. (41) 2020 | Retrospective study (24 months) | 20 RRMS | ↓ EDSS (2.6 ± 0.7 at b vs. 1.5 ± 0.5, p < 0.0001) | 2 patients new T2 lesions | No AE |
| Alemtuzumab     | Margoni et al. (42) 2019 | Case series (mean FU 3.9 years) | 5 RRMS | No relapse 3 patients had clinical improvement | No MRI activity | No SAE |
| Jure Hunt et al. (43) 2020 | Case series | 2 RRMS | No relapse EDSS improvement | No MRI activity | No SAE |
| Rituximab       | Dale et al. (44) 2014 | Multicenter retrospective study (mean FU 3.3) | 4 RRMS | Benefit: 1 definite, 0 probable, 1 possible, 1 none, 1 worsening | – | 12.5% AEs (anaphylaxis in 3, 11.7% infections, 2 deaths) |
| Salzer et al. (45) 2016 | Retrospective study (median FU 23.6 months) | 14 RRMS | EDSS stable in 93% of patients | 1 lesion detected on MRI | No AE |
| Cyclophosphamide | Makhani et al. (46) 2009 | Retrospective study (mean FU 2.7 years) | 23 RRMS | ↓ ARR (from 3.8 to 1.1, >70%) ↓ or stable EDSS in ≥80% | ↓ T2 and gad+ lesions (>75%) | Nausea and vomiting: 88% |
| Fingolimod      | Chitnis et al. (54) 2018 | Randomized, double-blind, phase III trial (PARADIGM) (24 months) | 215 RRMS | ↓ ARR (0.12 FTY vs. 0.67 IFN β; p < 0.001) ↓ T2 lesions (4.39 FTY vs. 9.27 IFN β; p < 0.001) | SAEs in 16.8% (infection, leukopenia, 6 patients had convulsions) |
| Huppke et al. (35) 2019 | Retrospective study (mean FU 31 months) | 23 RRMS | ↓ 75% ARR | ↓ 81% T2 lesions | – |
| Arnold et al. (16) 2020 | Randomized, double-blind, phase III trial (PARADIGM) (24 months) | 215 RRMS | – | ↓52.6% T2 lesions in FTY vs. IFN β (p < 0.001) ↓66% T1 lesions in FTY vs. IFN β (p < 0.001) | – |

B, baseline; EDSS, Expanded Disability Status Scale; FTY, fingolimod; FU, follow-up; IFN β, interferon β; Pbo, placebo; RR, relapse rate.
Anti-CD20 Therapies: Rituximab and Ocrelizumab

The first anti-CD20 monoclonal antibody (MAb) used in MS is the chimeric antibody rituximab, currently prescribed off-label in case of a highly active disease. In POMS, rituximab is one of the most used second-line immunosuppressive therapies.

In a case series of 14 POMS treated with rituximab for a median period of 23.6 months, a stable disease was observed in 13/14 patients (93%) with no SAE reported (45). However, in a cohort of 144 pediatric patients with autoimmune and inflammatory central nervous system (CNS) disorders (among which four POMS), infusion AEs were recorded in 18/144 (12.5%), including grade 4 (anaphylaxis) in three; 11 patients (7.6%) had infections, including two with grade 5 (death) and two with grade 4 (disabling) (+4). Furthermore, in a cohort of 1,019 pediatric patients with MS and clinically isolated syndromes, side effects and tolerability were similar to those reported in adults (14, 17). No rituximab-related PML cases have been reported in POMS. In the position paper of the International Pediatric MS Study Group, the potential benefit of rituximab was highlighted, but the need for a better evaluation of the optimal dosing, and the safety and efficacy profile were also stressed (13, 53).

Currently, there are no published reports of ocrelizumab use in POMS. An RCT evaluating the PK/PD and the efficacy of ocrelizumab 600 mg i.v. (300 mg i.v. if body weight < 40 kg) in POMS is in progress (https://clinicaltrials.gov/ct2/show/NCT04075266).

Alemtuzumab

A phase III RCT aimed to evaluate safety and efficacy of alemtuzumab in POMS patients who have failed at least two DMDs is in progress (NCT03368664). Some observational reports showed that alemtuzumab was relatively well-tolerated and effective in POMS; indeed, no serious infusion reactions, infections, or relapses were recorded during the follow-up (42, 43).

Cyclophosphamide

Several studies have suggested that cyclophosphamide treatment may be most beneficial in younger adult MS patients (54–56). A single, multicenter retrospective study of 17 cyclophosphamide-treated POMS with a mean follow-up of 2.7 years showed a reduction in ARR (from 3.8 to 1.1), and stabilization of disability scores assessed 1 year after treatment initiation in most patients (83%) compared with baseline. Furthermore, a reduction in new/enlarged T2 hyperintense lesions and Gd-enhancing lesions was observed (100 vs. 75% and 91 vs. 67%, respectively) (46). The most frequent AEs included vomiting, transient alopecia, osteoporosis, and amenorrhea. One patient developed bladder carcinoma that was successfully treated (46).

Mitoxantrone

Given the risk of cardiotoxicity and acute myeloid leukemia (57), the use of mitoxantrone in POMS is discouraged.

FUTURE PERSPECTIVES AND CONCLUSIONS

POMS is a rare but severe form of MS, characterized by a more prominent clinical and radiological activity and younger age at reaching cognitive and physical disability milestones, even when treated with first-line DMDs. Furthermore, adherence to injectable DMDs is an important determinant of treatment efficacy in real-world clinical settings. Off-label use of newer DMDs is increasing in POMS and retrospective studies, case series, and phase II trials, indicate that this approach appears to be highly effective and safe in children. However, great efforts should be devoted to design RCTs in POMS. The low number of patients and the potentially severe long-term prognosis strongly indicate the necessity of identifying new and adequately powered MRI targets (e.g., annualized rate of brain atrophy) of treatment as well as more specific clinical (especially cognitive) endpoints for this peculiar MS population. Moreover, the harmonization of regulatory requirements for testing of new treatment should be prioritized to compare clinical trials with one another (33).

Although more data are needed before standardizing the use of first- and second-line newer therapies in POMS, the treatment paradigm implies to design therapeutic strategies based on highly effective drugs. Thus, the approval of fingolimod and the availability of high-efficacy Mab constitute a real step-forward in POMS management.

AUTHOR CONTRIBUTIONS

MM, PG, FR, and PP: design and drafting of the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. (2009) 66:54–9. doi: 10.1001/archneurol.2008.505
2. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. (2009) 66:967–71. doi: 10.1001/archneurol.2009.135
3. Baruch NF, O’Donnell EH, Glanz BI, Benedict RH, Musallam AJ, Healy BC, et al. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler. (2016) 22:354–61. doi: 10.1177/1352458515588781
4. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. (2007) 356:2603–13. doi: 10.1056/NEJMoa067597
5. McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology. (2019) 92:e2764–73. doi: 10.1212/WNL.0000000000007647
6. McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J. Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis. JAMA Neurol. (2019) 76:1028–34. doi: 10.1001/jamaneurol.2019.1546
24. Makhani N, Schreiner T. Oral dimethyl fumarate in children with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. (2018) 83:19–24. doi: 10.1016/j.pediatrneurol.2018.03.007

25. Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, Blaschek A, Valis M, Aeen G, et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol. (2020) 11:60618. doi: 10.3389/fneur.2020.60618

26. Chitnis T, Banwell B, Arnold D, Gucuyener K, Deiva K, Skripchenko N, et al. Teriflunomide efficacy and safety in pediatric patients with relapsing forms of MS: interim analysis of the open-label TERIKIDS trial extension. ECTRIMS. Virtual (2020).

27. Ghezzi A. Immunomodulatory Treatment of Early Onset MS. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian co-operative study. Neurol Sci. (2005) 26 (Suppl. 4):S183–6. doi: 10.1007/s10072-005-0512-8

28. Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. (2005) 64:888–90. doi: 10.1212/01.WNL.0000153570.33845.6A

29. Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. (2011) 68:437–44. doi: 10.1001/archneurol.2010.325

30. Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon Beta-1a in multiple sclerosis: a retrospective study. J Child Neurol. (2015) 28:849–56. doi: 10.1177/0883073814588828

31. Ghezzi A. Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord. (2010) 3:217–28. doi: 10.1177/1756285610371251

32. Waubant E, Banwell B, Wassmer E, Sormani MP, Amato MP, Hintzen R, et al. Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG. Neurology. (2019) 92:e2538–49. doi: 10.1212/WNL.0000000000007572

33. Chitnis T, Arnold DL, Banwell B, Bruck W, Ghezzi A, Giovanni G, et al. Trial of fingolimod vs. interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. (2018) 379:1017–27. doi: 10.1056/NEJMoai1800149

34. Huppke P, Huppke B, Ellenberger D, Rostasy K, Hummel H, Stark W, et al. Therapy of highly active pediatric multiple sclerosis. Mult Scler. (2019) 25:72–80. doi: 10.1177/1352458517732843

35. Fragoso YD, Alves-Leon SV, Barreira AA, Callegaro D, Brito Ferreira ML, Finkelstein A, et al. Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years. Pediatr Neurol. (2015) 53:166–8. doi: 10.1016/j.pediatrneurol.2015.03.024

36. Kornke B, Aboul-Enein F, Rostasy K, Milos RL, Steiner I, Penzijn J, et al. Natalizumab therapy for highly active pediatric multiple sclerosis. JAMA Neurol. (2013) 70:469–75. doi: 10.1001/jamaneurol.2013.923

37. Arnal-Garcia C, Garcia-Montero MR, Malaga I, Milian-Pascual J, Oliva-Nazarino P, Ramio-Torrenta L, et al. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. Eur J Paediatr Neurol. (2013) 17:50–4. doi: 10.1016/j.ejpn.2012.09.004

38. Ghezzi A, Pozzilli C, Grimaldi LM, Moiola A, Lrescia-Morra V, Lugarasi A, et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. (2013) 19:1106–12. doi: 10.1177/1352458512471788

39. Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. (2015) 15:174. doi: 10.1186/s12883-015-0433-y

40. Margoni M, Rinaldi F, Miante S, Franciotta S, Perini P, Gallo P. No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab. J Neurol. (2020) 267:100–5. doi: 10.1007/s00415-019-09554-z

41. Margoni M, Rinaldi F, Miante S, Franciotta S, Perini P, Gallo P. Aletumumab following natalizumab in highly active paediatric-onset multiple sclerosis. Mult Scler J Exp Transl Clin. (2019) 5. doi: 10.1177/2055217319875471

42. Jure Hunt D, Traboulsee A. Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. Mult Scler J Exp Transl Clin. (2020) 6. doi: 10.1177/2055217320946131

43. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. (2014) 83:142–50. doi: 10.1212/WNL.0000000000005570
45. Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. (2016) 263:322–6. doi: 10.1007/s00415-015-7979-x
46. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. (2009) 72:2076–82. doi: 10.1212/WNL.0b013e3181a8164c
47. Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. (2010) 75:912–7. doi: 10.1212/WNL.0b013e3181f11daf
48. Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, et al. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurol Neuroimmunol Neuroinflamm. (2019) 6:e591. doi: 10.1212/NXI.0000000000000591
49. Margoni M, Gallo P. Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic. Mult Scler J Exp Transl Clin. (2020) 6:2055217320966346. doi: 10.1177/2055217320966346
50. Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, et al. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler. (2015) 21:382–7. doi: 10.1177/1352458514543340
51. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. (2009) 5:e1000363. doi: 10.1371/journal.ppat.1000363
52. Trampe AK, Hemmelmann C, Stroet A, Haghihia A, Hellwig K, Wiendl H, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. (2012) 78:1736–42. doi: 10.1212/WNL.0b013e3182583022
53. Ghezzi A, Banwell B, Bar-Or A, Chitnis T, Dale RC, Gorman M, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: practical considerations. Mult Scler. (2020). doi: 10.1177/1352458520932798. [Epub ahead of print].
54. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the northeast cooperative multiple sclerosis treatment group. Neurology. (1993) 43:910–8. doi: 10.1212/WNL.43.5.910
55. Hommers OR, Lamers KJ, Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol. (1980) 223:177–90. doi: 10.1007/BF00313182
56. Gonsette RE, Demonty L, Delmote P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol. (1977) 214:173–81. doi: 10.1007/BF00316148
57. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW, Therapeutics, Technology Assessment Subcommittee of the American Academy of N. Evidence report: the efficacy and safety of mitoxantrone (Novantron) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. (2010) 74:1463–70. doi: 10.1212/WNL.0b013e3181d1ae0

Conflict of Interest: MM reports grants and personal fees from Sanofi Genzyme, Merck Serono, Novartis and Almirall. She was awarded a MAGNIMS-ECTRIMS fellowship in 2020. FR reports grants and personal fees from Genzyme Sanofi, Merck Serono, Biogen Idec, grants from Novartis, during the conduct of the study. PP reports grants and personal fees from Merck Serono, Biogen Idec, Genzyme Sanofi, Roche, Novartis, during the conduct of the study. PG reports grants and personal fees from Merck Serono, Biogen Idec, Genzyme Sanofi, grants and personal fees from Novartis, grants from University of Padua, Department of Neurosciences DNS, grants from Veneto Region of Italy, grants from Italian Association for Multiple Sclerosis (AISM), grants from Italian Ministry of Public Health, during the conduct of the study.